Institute of Cancer Research http://www.icr.ac.uk The Institute of Cancer Research is one of the world’s leading cancer research organisations and cancer charities. In partnership with The Royal Marsden NHS Foundation Trust, The ICR specialises in cancer diagnosis, cancer treatment and cancer education Wed, 22 Feb 2012 19:07:26 +0000 en hourly 1 New MRI technique predicts treatment response for neuroendocrine cancer patients http://www.icr.ac.uk/press/press_archive/press_releases_2012/22547.shtml Fri, 17 Feb 2012 00:00:00 +0000 ICR News http://www.icr.ac.uk/press/press_archive/press_releases_2012/22547.shtml Scientists at the ICR and The Royal Marsden have shown that a specialist type of MRI scan can be used to predict which patients will respond to a targeted radiotherapy and monitor response to treatment. Hundreds more breast cancer patients should be tested for BRCA1 gene http://www.icr.ac.uk/press/press_archive/press_releases_2012/22539.shtml Wed, 15 Feb 2012 00:00:00 +0000 ICR News http://www.icr.ac.uk/press/press_archive/press_releases_2012/22539.shtml Leading breast cancer experts are calling for women under 50 who are diagnosed with triple-negative breast cancer to be offered testing for faults in the BRCA1 gene, according to a report published in the British Journal of Cancer today. Report reveals year of research success http://www.icr.ac.uk/press/press_archive/press_releases_2012/22489.shtml Thu, 2 Feb 2012 00:00:00 +0000 ICR News http://www.icr.ac.uk/press/press_archive/press_releases_2012/22489.shtml The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have launched their Joint Annual Research Report for 2010/11, highlighting a year of significant achievements. Prostate cancer drug shows impressive new Phase III trial results http://www.icr.ac.uk/press/press_archive/press_releases_2012/22486.shtml Wed, 1 Feb 2012 00:00:00 +0000 ICR News http://www.icr.ac.uk/press/press_archive/press_releases_2012/22486.shtml Patients with advanced prostate cancer who were given a new type of hormonal treatment called MDV3100 lived an extra 4.8 months compared to men taking a placebo, according to the full analysis of a Phase III trial. Women with faulty BRCA genes more likely to survive ovarian cancer http://www.icr.ac.uk/press/press_archive/press_releases_2012/22455.shtml Tue, 24 Jan 2012 00:00:00 +0000 ICR News http://www.icr.ac.uk/press/press_archive/press_releases_2012/22455.shtml Ovarian cancer patients who carry BRCA1 or BRCA2 mutations are significantly more likely to survive the disease than women without these faulty genes, according to research published in the Journal of the American Medical Association. Musculoskeletal side–effects from breast cancer treatment are not long term http://www.icr.ac.uk/press/press_archive/press_releases_2012/22453.shtml Fri, 20 Jan 2012 00:00:00 +0000 ICR News http://www.icr.ac.uk/press/press_archive/press_releases_2012/22453.shtml A drug regimen found to cut a women’s risk of dying from breast cancer gives a higher risk of carpal tunnel syndrome, but this can be managed and does not persist once treatment has finished. Scientists unravel cause of second cancer arising from targeted treatment http://www.icr.ac.uk/press/press_archive/press_releases_2012/22446.shtml Wed, 18 Jan 2012 00:00:00 +0000 ICR News http://www.icr.ac.uk/press/press_archive/press_releases_2012/22446.shtml Scientists at The Institute of Cancer Research (ICR) have shown how to prevent new cancers which can occur when malignant melanoma patients are treated with drugs known as BRAF inhibitors, in a Cancer Research UK-funded study published today in the New England Journal of Medicine. Scientist wins prestigious fellowship http://www.icr.ac.uk/press/press_archive/press_releases_2012/22407.shtml Tue, 10 Jan 2012 00:00:00 +0000 ICR News http://www.icr.ac.uk/press/press_archive/press_releases_2012/22407.shtml A scientist from the ICR and The Royal Marsden has received one of four prestigious Cancer Research UK Clinical Scientist Fellowships for his research into new ways to detect and treat advanced prostate cancer. Fewer, Larger Radiotherapy Doses Prove Safe For Prostate Cancer Patients http://www.icr.ac.uk/press/press_archive/press_releases_2011/22355.shtml Tue, 13 Dec 2011 00:00:00 +0000 ICR News http://www.icr.ac.uk/press/press_archive/press_releases_2011/22355.shtml Less overall radiotherapy, delivered in fewer but higher doses, is as safe as standard, lower doses for treating prostate cancer, according to new research. Scientists Discover How To Beat Resistance To Standard Leukaemia Drug http://www.icr.ac.uk/press/press_archive/press_releases_2011/22292.shtml Thu, 8 Dec 2011 00:00:00 +0000 ICR News http://www.icr.ac.uk/press/press_archive/press_releases_2011/22292.shtml ICR scientists have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according to research published in Cancer Cell